Financial Perspectives, Inc Alkermes Plc. Transaction History

Financial Perspectives, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Jan 09, 2024	SELL	$23.37 - $32.13 $32,133 - $44,178	-1,375 Closed	0 $0
Q2 2021 Jan 09, 2024	SELL	$18.78 - $25.15 $456,541 - $611,396	-24,310 Reduced 94.65%	1,375 $33.7 Million
Q1 2021 Jan 09, 2024	BUY	$18.21 - $23.2 $442,685 - $563,992	24,310 Added 1768.0%	25,685 $1.38 Million
Q4 2019 Jan 09, 2024	BUY	$17.29 - $21.74 $23,773 - $29,892	1,375 New	1,375 $28.1 Million

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.88B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Financial Perspectives, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Perspectives, Inc with notifications on news.